Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/3/2026

1. PANW
2. SPY
3. ULTA
4. GTLB
5. USO
6. CRWD
7. GOOGL
8. MDT
9. AVGO
10. VRTS

Go back to Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

February 4, 2026 6:45 AM EST

Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and... More